Improving outcomes of refractory celiac disease - current and emerging treatment strategies.

Early studies showed promising subjective and histological responses in both RCD1 and RCD2, 72 , 73 but a worrying trend to increasing progression to EATL in RCD2. 73 Good responses have been reported in RCD1 but not subsequently in RCD2. 38 Limiting its use to RCD1, the azathioprine metabolite, thioguanine (tioguanine), achieved an 83% clinical response and 78% histological response, but there was still a considerab

also in 390 other papers